ACE-031 1 mg (recombinant human ActRIIB-Fc; “ramatercept”) from Peptide Tech is a dimeric research-use-only (RUO) fusion protein consisting of the extracellular domain of Activin Receptor Type IIB (ACVR2B) fused to the human IgG1 Fc region. Supplied lyophilized with rigorous documentation and cold-chain integrity, ACE-031 is designed for in-vitro ligand-trap studies across the TGF-β/activin/myostatin axis, SMAD2/3 reporter workflows, and high-specificity binding/neutralization assays.
Specifications
| Property | Details |
|---|---|
| Product | ACE-031 (ActRIIB-Fc), lyophilized protein |
| Content per Vial | 1 mg |
| Chemical Name | Recombinant human Activin Receptor Type IIB extracellular domain fused to human IgG1 Fc (dimeric glycoprotein) |
| Synonyms | ActRIIB-Fc; ACVR2B-Fc; soluble ActRIIB; ramatercept |
| CAS Number | Not assigned (biologic fusion protein) |
| PubChem CID | No PubChem small-molecule record (protein biologic). See UniProt ACVR2B Q13705 and IgG1 Fc P01857. |
| Sequence / Architecture | Human ACVR2B extracellular domain (typ. Ser19–Thr134)–hinge–human IgG1 Fc (CH2–CH3). Exact construct boundaries and tags are provided on the lot-specific COA. |
| Molecular Weight | ~100–110 kDa (dimer, non-reducing); ~50–60 kDa (monomer, reducing). Apparent mass varies with glycosylation. |
| Appearance | White to off-white lyophilized cake/powder |
| Purity / Identity | ≥95% by SDS-PAGE; identity by intact MS/peptide mapping; SEC-HPLC profile per COA |
| Endotoxin | Per-lot value reported on COA (third-party U.S. lab) |
| Solubility / Buffer | Reconstitute in sterile water or PBS (pH 7.2–7.4) to 0.2–1.0 mg/mL. For long-term aliquots, include carrier (e.g., 0.1% BSA or 5–10% trehalose) per your SOP. |
| Container | 3 mL Type I glass vial; butyl stopper; flip-off seal |
| Storage (lyophilized) | −20 °C long-term (desiccated, light-protected) |
| After Reconstitution | Aliquot immediately; store ≤−20 °C (preferably −80 °C for extended periods). Avoid repeated freeze–thaw. |
| Intended Use | Laboratory research only (RUO). Not for human or animal use. |
Molecular Structure
No 2D PubChem structure is available for this Fc-fusion protein. For reference domain structures and constructs, see ACVR2B (UniProt Q13705) and IgG1 Fc (UniProt P01857), and fused receptor-trap structures (e.g., PDB 7MRZ).
Key Features of Peptide Tech
- Same-Day Shipping (Mon–Fri, on in-stock items)
- GMP-Aligned lyophilization, documentation & traceability
- USA-Made biologics
- 24/7 Support & Price Match Guarantee
- Batch QR for instant COA & chain-of-custody verification
- 3rd-Party U.S. Lab Testing — purity, quantity, endotoxin
- Cold-Chain Shipping — Always (no paid upgrade)
- Worldwide Shipping; all major payments accepted
- Text & Email order updates; 2-Day FedEx/UPS standard with low-cost overnight
- Largest Variety of peptides, proteins & bioregulators
Potential Applications in Research (RUO)
Strictly for in-vitro, cell-based, or biochemical experiments. No health, diagnostic, or therapeutic claims.
- Ligand-trap & neutralization assays — quantify sequestration of myostatin (GDF-8), activin A, GDF11, and related ligands using ELISA/biochemical readouts or SMAD2/3 phosphorylation endpoints in responsive cell lines. Review context; decoy receptor background.
- SMAD reporter workflows — run luciferase reporters (CAGA-luc/SMAD2-3) to profile concentration-dependent inhibition of activin/myostatin signaling by ActRIIB-Fc in defined media. Pathway overview.
- BLI/SPR binding kinetics — determine on/off-rates and apparent affinities for ligand panels with immobilized ACE-031 or ligands; compare to published ActRIIB-Fc kinetics. Kinetic characterization.
- Endothelial/BMP9-10 pathway studies — interrogate BMP9/10-dependent signaling and its attenuation in endothelial models where type-II receptor engagement is required. Ligand-trap structures.
- Analytical method development — establish SEC-HPLC, SDS-PAGE, intact-MS/peptide-mapping, and endotoxin assays for Fc-fusion biologics; verify stability across buffers, pH, and temperatures (forced-degradation).
Citations (MLA)
- Lee, Sangmin J., and Glenn A. Walter. “Targeting the Myostatin Signaling Pathway to Treat Muscle Loss.” Journal of Clinical Investigation, vol. 131, no. 10, 2021. https://www.jci.org/articles/view/148372.
- Zimmerman, Christopher M., et al. “Characterization of the Ligand Binding Functionality of the Activin Receptor Type IIB Using a Soluble ActRIIB-Fc Chimera.” Journal of Biological Chemistry, 2009. Link.
- Eguchi, Junichi, et al. “A Decoy Receptor (ACVR2B/Fc) Potently Inhibits Myostatin/Activin Signaling.” Proceedings of the National Academy of Sciences, 2020. PDF.
- Nickerson, Jennifer L., et al. “Structures of Activin Ligand Traps Using Natural Sets of Type I and Type II TGF-β Receptors.” iScience, vol. 25, no. 2, 2022. Link.
- UniProt Consortium. “ACVR2B — Activin Receptor Type-2B (Human).” UniProtKB (Q13705). Link.
Quality, Storage & Handling
Every lot is accompanied by a COA confirming purity (SDS-PAGE/SEC-HPLC), identity (MS/peptide-mapping), and endotoxin testing by independent U.S. labs. The on-vial QR links directly to batch documentation.
- Reconstitution: Bring to room temperature; add sterile water or PBS gently to the vial wall. Avoid vigorous vortexing; invert or swirl to dissolve. Filter (0.22 µm) if your SOP requires sterility.
- Stabilizers: For storage beyond 24–48 h in solution, prepare single-use aliquots with carrier (e.g., 0.1% BSA or 5–10% trehalose) and freeze promptly.
- Controls: Include ligand-only, isotype Fc, and dose-response controls for unambiguous pathway interpretation.
Shipping & Fulfillment
Ships with validated cold-chain packaging. In-stock orders placed before the daily cutoff ship the same day. 2-Day FedEx/UPS is standard, with overnight options available. Automated text/email updates included; international shipping available where permitted.
Compliance & RUO Disclaimer
For laboratory research only. Not a drug, cosmetic, food, or household chemical. Not for human or animal use, ingestion, diagnostic, or therapeutic applications. Purchasers warrant appropriate qualifications and compliance with applicable regulations and institutional policies.
FAQs
- Is ACE-031 a peptide?
- No. ACE-031 is a recombinant Fc-fusion protein (ActRIIB extracellular domain fused to human IgG1 Fc), not a short peptide.
- Do you provide a PubChem structure image?
- PubChem does not host a 2D structure for this biologic. See domain references on UniProt (ACVR2B Q13705; IgG1 Fc P01857) and fused-trap structures (e.g., PDB 7MRZ) linked above.
- What purity and testing do you provide?
- Each 1 mg vial is confirmed by SDS-PAGE/SEC-HPLC with MS/peptide-mapping identity; endotoxin testing is performed by third-party U.S. labs (see COA via on-vial QR).
- How should I store reconstituted ACE-031?
- Prepare single-use aliquots; store at ≤−20 °C (preferably −80 °C) and avoid repeat freeze–thaw. Include stabilizer per your SOP.
Explore More
Browse additional peptides, proteins, and accessories at Peptide Tech.











